Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Trial Profile

Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Nelarabine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 30 Oct 2017 Status changed from recruiting to completed.
    • 24 Apr 2017 Planned End Date changed from 18 Aug 2018 to 18 Oct 2017.
    • 24 Apr 2017 Planned primary completion date changed from 18 Aug 2018 to 18 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top